Abstract:BACKGROUND: Precise recipient selection optimizes the prognosis of liver transplantation (LT) for hepatocellular carcinoma (HCC). Alpha-fetoprotein (AFP) is the most commonly used biomarker for diagnosis and prognosis of HCC in the clinical context. As a crucial molecule in methionine cycle, homocysteine (Hcy) level has been proved to be related to HCC progression and metastasis. OBJECTIVE: We aimed to explore the prognostic capacity of pre-transplant serum Hcy level in LT for HCC. METHODS: This study retrospectively enrolled 161 HCC patients who had underwent LT from donation after cardiac death (DCD) in the First Affiliated Hospital of Zhejiang University from 2015.01.01 to 2018.09.01. Pre-transplant serum Hcy level was incorporated into statistical analysis together with other clinical parameters and pathological features. RESULTS: From an overall perspective, significant difference was observed in Hcy level between recurrence (n= 61) and non-recurrence group (n= 100) though subsequent analysis showed unsatisfactory predicting performance. In the whole cohort, multivariate analysis showed that lnAFP (p= 0.010) and Milan criteria (MC, p< 0.001) were independent risk factors of HCC recurrence after LT. MA score based on MC and lnAFP performed well in predicting post-LT tumor recurrence with the AUROC at 0.836 (p< 0.001) and 3-year recurrence-free survival rate at 96.8% (p< 0.001) in the low risk group (n= 69). According to the clinical practice, serum concentration lower than 20 μg/L is considered as normal range of AFP. Elevated pre-transplant serum AFP (> 20 μg/L) predicts high HCC recurrence after LT. We further divided the 161 recipients into AFP- group (n= 77, AFP ⩽ 20 μg/L) and AFP+ group (n= 84, AFP > 20 μg/L). MA score was still well presented in the AFP+ group and the AUROC for tumor recurrence was 0.823 (p< 0.001), whereas the predicting accuracy was reduced in AFP- group (AUROC: 0.754, P< 0.001). After subsequent analysis, we found that elevated pre-transplant Hcy level (> 12.75 μmol/L) predicted increased tumor recurrence risk in AFP- group. The 3-year recurrence-free survival rates were 92.0% and 53.7% (p< 0.001) in low Hcy subgroup (n= 40) and high Hcy subgroup (n= 37) respectively. Multivariate analysis showed that Hcy (p= 0.040) and Milan criteria (p= 0.003) were independent risk factors for post-transplant tumor recurrence in AFP- group. Further combination of Hcy level and Milan criteria identified a subgroup of AFP- recipients with acceptable outcomes even though beyond Milan criteria (3-year recurrence-free survival rate: 77.7%, p< 0.001). CONCLUSION: As a classic predictor in HCC prognosis, AFP performed well in our study cohort when combined with Milan criteria. Homocysteine was an effective prognostic biomarker in LT for AFP- hepatocellular carcinoma. In recipients exceeding Milan criteria, acceptable post-transplant outcome could be seen in those with low Hcy and AFP level.

The Value of Serum α-Fetoprotein in Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma

Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation.

The value of serum alpha-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma.

Relationship Between Clinicopathologic Features and Neoplasm Recurrence,prognosis in Hepatocellular Carcinoma after Liver Transplantation

Predictive Value of Alpha-fetoprotein in the Survival of Living Donor Liver Transplantation Recipients for Hepatocellular Carcinoma.

Prognostic Significance of Preoperative Serum Alpha- Fetoprotein in Hepatocellular Carcinoma and Correlation with Clinicopathological Factors: a Single-center Experience from China.

A Case-Control Study of Correlation Between Preoperative Serum Afp and Recurrence of Hepatocellular Carcinoma after Curative Hepatectomy

Alpha-fetoprotein and 18F-FDG Standard Uptake Value Predict Tumor Recurrence after Liver Transplantation for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Preliminary Experience.

[Multivariate Analysis of Recurrence of Hepatocellular Carcinoma after Liver Transplantation].

Relationship Between Pre-Transplantation Α-Fetoprotein Messenger RNA Expression in Peripheral Blood with Tumor Recurrence and Survival Rate in HCC Patients

Risk Factors for Fatal Recurrence of Hepatocellular Carcinoma and Their Role in Selecting Candidates for Liver Transplantation

[Study on the Value of Serum Des-Γ-carboxy Prothrombin in Predicting Hepatocellular Carcinoma Recurrence after Liver Transplantation].

Prediction of Early Recurrence of Hepatocellular Carcinoma in Patients with Cirrhosis Who Had Received Deceased Donor Liver Transplantation: A Multicenter Study.

Correlation Between Preoperative Serum Alpha-Fetoprotein (AFP) Level and Early Recurrence of Patients with Hepatocellular Carcinoma after Partial Hepatectomy

Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation

Homocysteine: A Novel Prognostic Biomarker in Liver Transplantation for Alpha-Fetoprotein- Negative Hepatocellular Carcinoma

Changes in Serum Alpha Fetoprotein in Patients with Recurrent Hepatocellular Carcinoma Following Hepatectomy.

The Prognostic Values of Serum Markers in Hepatocellular Carcinoma after Invasive Therapies Based on Real‐world Data

The Predictive Value of the Modified AFP Model for Liver Transplantation Outcomes in Multinodular Hepatocellular Carcinoma Patients

Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma

Alpha Fetoprotein Changes Predict Hepatocellular Carcinoma Survival Beyond the Milan Criteria after Hepatectomy.